Strides Pharma Science Limited (BOM:532531)

Strides Pharma Science Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	1,368	1,610	3,035	1,707	1,258
Short-Term Investments	695	227.8	63.63	134.55	1,490
Trading Asset Securities	-	1,058	508.4	-	-
Cash & Short-Term Investments	2,063	2,896	3,607	1,842	2,749
Cash Growth	-28.76%	-19.72%	95.84%	-32.99%	-20.88%
Accounts Receivable	12,029	11,419	12,994	12,073	11,106
Other Receivables	-	1,462	936.49	5,899	367.53
Receivables	12,134	13,008	14,008	18,020	11,514
Inventory	12,776	11,262	11,465	11,738	12,007
Prepaid Expenses	-	706.94	639.29	541.85	526.86
Other Current Assets	4,017	1,817	2,714	1,476	1,376
Total Current Assets	30,989	29,690	32,434	33,618	28,172
Property, Plant & Equipment	9,803	9,585	13,726	15,136	14,994
Long-Term Investments	3,397	2,015	4,422	5,416	6,120
Goodwill	5,466	5,294	5,138	4,859	4,805
Other Intangible Assets	5,680	5,271	5,631	6,250	6,185
Long-Term Deferred Tax Assets	2,691	2,673	2,650	2,151	1,982
Other Long-Term Assets	2,461	3,368	2,385	2,297	7,787
Total Assets	60,487	58,398	66,384	69,759	70,150
Accounts Payable	10,325	8,516	9,823	10,715	11,342
Accrued Expenses	-	1,229	1,287	1,348	1,318
Short-Term Debt	-	15,742	13,308	14,965	10,238
Current Portion of Long-Term Debt	12,244	1,689	3,039	4,598	1,970
Current Portion of Leases	325.62	307.05	514.39	465.98	345.7
Current Income Taxes Payable	340.37	404.16	267.11	238.11	351.18
Other Current Liabilities	2,681	905.91	1,664	1,786	1,819
Total Current Liabilities	25,915	28,793	29,902	34,117	27,383
Long-Term Debt	5,712	6,715	11,398	8,356	8,826
Long-Term Leases	514.58	716.35	2,037	1,865	2,103
Long-Term Unearned Revenue	-	-	-	-	1.08
Long-Term Deferred Tax Liabilities	1,194	403.45	445.71	357.19	463.48
Other Long-Term Liabilities	1,287	504.78	464.61	780.18	2,829
Total Liabilities	34,623	37,680	44,655	45,925	42,010
Common Stock	921.63	919	903.03	897.9	896.81
Additional Paid-In Capital	-	18,233	17,545	17,322	17,273
Retained Earnings	-	1,197	2,037	4,060	8,865
Comprehensive Income & Other	24,597	906.9	1,638	1,312	731.94
Total Common Equity	25,518	21,256	22,123	23,592	27,767
Minority Interest	346.33	-538.57	-393.75	240.88	373.41
Shareholders' Equity	25,865	20,717	21,729	23,833	28,140
Total Liabilities & Equity	60,487	58,398	66,384	69,759	70,150
Total Debt	18,796	25,169	30,296	30,250	23,482
Net Cash (Debt)	-16,734	-22,273	-26,689	-28,408	-20,734
Net Cash Per Share	-181.84	-244.75	-296.27	-316.54	-231.12
Filing Date Shares Outstanding	92.15	91.9	90.3	89.8	89.68
Total Common Shares Outstanding	92.15	91.9	90.3	89.79	89.68
Working Capital	5,074	897.4	2,532	-498.44	788.86
Book Value Per Share	276.93	231.29	244.98	262.75	309.62
Tangible Book Value	14,373	10,690	11,354	12,483	16,776
Tangible Book Value Per Share	155.98	116.33	125.73	139.03	187.06
Land	-	1,416	1,410	1,383	1,041
Buildings	-	3,225	3,844	4,205	2,857
Machinery	-	9,048	12,539	13,042	11,264
Construction In Progress	-	798.79	482.59	562.29	2,276

Updated Jan 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.